[1] G.J. Ghebreyesus LA, Al-Ansary LA, World health organization global health observatory statistic :Geneva 2018, 2018. 380 (2018) 1–100. https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf.
[2] R.M. Feng, Y.N. Zong, S.M. Cao, R.H. Xu, Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics?, Cancer Communications. 39 (2019). https://doi.org/10.1186/s40880-019-0368-6.
[3] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians. 68 (2018) 394–424. https://doi.org/10.3322/caac.21492.
[4] V. Gilsanz García, Hepatocellular carcinoma, Anales de La Real Academia Nacional de Medicina. 105 (1988) 387–409. https://doi.org/10.1056/NEJMra1713263.
[5] A. Marengo, C. Rosso, E. Bugianesi, Liver cancer: Connections with obesity, fatty liver, and cirrhosis, Annual Review of Medicine. 67 (2016) 103–117. https://doi.org/10.1146/annurev-med-090514-013832.
[6] R.K. Phukan, B.J. Borkakoty, S.K. Phukan, K. Bhandari, J. Mahanta, S. Tawsik, S. Bhandari, A. Rai, K. Narain, Association of processed food, synergistic effect of alcohol and HBV with Hepatocellular Carcinoma in a high incidence region of India, Cancer Epidemiology. 53 (2018) 35–41. https://doi.org/10.1016/j.canep.2018.01.005.
[7] A. Forner, M. Reig, J. Bruix, Hepatocellular carcinoma, The Lancet. 391 (2018) 1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2.
[8] D.M. Parkin, The global health burden of infection-associated cancers in the year 2002, International Journal of Cancer. 118 (2006) 3030–3044. https://doi.org/10.1002/ijc.21731.
[9] M.E. Rinella, Nonalcoholic fatty liver disease a systematic review, JAMA - Journal of the American Medical Association. 313 (2015) 2263–2273. https://doi.org/10.1001/jama.2015.5370.
[10] A. Mirizzi, I. Franco, C.M. Leone, C. Bonfiglio, R. Cozzolongo, M. Notarnicola, V. Giannuzzi, V. Tutino, V. De Nunzio, I. Bruno, C. Buongiorno, A. Campanella, V. Deflorio, A. Pascale, F. Procino, P. Sorino, A.R. Osella, Effects of some food components on non-alcoholic fatty liver disease severity: Results from a cross-sectional study, Nutrients. 11 (2019). https://doi.org/10.3390/nu11112744.
[11] C.D. Mathers, D. Loncar, Projections of global mortality and burden of disease from 2002 to 2030, PLoS Medicine. 3 (2006) 2011–2030. https://doi.org/10.1371/journal.pmed.0030442.
[12] A. Jemal, E.M. Ward, C.J. Johnson, K.A. Cronin, J. Ma, A.B. Ryerson, A. Mariotto, A.J. Lake, R. Wilson, R.L. Sherman, R.N. Anderson, S.J. Henley, B.A. Kohler, L. Penberthy, E.J. Feuer, H.K. Weir, Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival, Journal of the National Cancer Institute. 109 (2017). https://doi.org/10.1093/jnci/djx030.
[13] M. Taskinen, M.L. Karjalainen-Lindsberg, H. Nyman, L.M. Eerola, S. Leppä, A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide- doxorubicin-vincristine-prednisone, Clinical Cancer Research. 13 (2007) 5784–5789. https://doi.org/10.1158/1078-0432.CCR-07-0778.
[14] L. Zhou, Y. Huang, J. Li, Z. Wang, The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma, Medical Oncology. 27 (2010) 255–261. https://doi.org/10.1007/s12032-009-9201-4.
[15] L. Kulik, H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma, Gastroenterology. 156 (2019) 477-491.e1. https://doi.org/10.1053/j.gastro.2018.08.065.
[16] D. Dimitroulis, C. Damaskos, S. Valsami, S. Davakis, N. Garmpis, E. Spartalis, A. Athanasiou, D. Moris, S. Sakellariou, S. Kykalos, G. Tsourouflis, A. Garmpi, I. Delladetsima, K. Kontzoglou, G. Kouraklis, From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world, World Journal of Gastroenterology. 23 (2017) 5282–5294. https://doi.org/10.3748/wjg.v23.i29.5282.
[17] S. Liu, X. Yao, D. Zhang, J. Sheng, X. Wen, Q. Wang, G. Chen, Z. Li, Z. Du, X. Zhang, Analysis of Transcription Factor-Related Regulatory Networks Based on Bioinformatics Analysis and Validation in Hepatocellular Carcinoma, BioMed Research International. 2018 (2018). https://doi.org/10.1155/2018/1431396.
[18] L. Li, Q. Lei, S. Zhang, L. Kong, B. Qin, Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis, Oncology Reports. 38 (2017) 2607–2618. https://doi.org/10.3892/or.2017.5946.
[19] C. Zhang, L. Peng, Y. Zhang, Z. Liu, W. Li, S. Chen, G. Li, The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data, Medical Oncology. 34 (2017). https://doi.org/10.1007/s12032-017-0963-9.
[20] Z. Song, Y. Duan, S. Wan, X. Sun, Q. Zou, H. Gao, D. Zhu, Processing Optimization of Typed Resources with Synchronized Storage and Computation Adaptation in Fog Computing, Wireless Communications and Mobile Computing. 2018 (2018). https://doi.org/10.1155/2018/3794175.
[21] M. Song, Y. Duan, T. Huang, L. Zhan, Inter-Edge and Cloud conversion accelerated user-generated content for virtual brand community, Eurasip Journal on Wireless Communications and Networking. 2020 (2020). https://doi.org/10.1186/s13638-019-1635-6.
[22] Y. Duan, Z. Lu, Z. Zhou, X. Sun, J. Wu, Data Privacy Protection for Edge Computing of Smart City in a DIKW Architecture, Engineering Applications of Artificial Intelligence. 81 (2019) 323–335. https://doi.org/10.1016/j.engappai.2019.03.002.
[23] Y. Totoki, et al., Trans-ancestry mutational landscape of hepatocellular carcinoma genomes, Nature Genetics. 46 (2014) 1267–1273. https://doi.org/10.1038/ng.3126.
[24] A. Ally, et al., Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma, Cell. 169 (2017) 1327-1341.e23. https://doi.org/10.1016/j.cell.2017.05.046.
[25] L.S.E.P.W. Castro, T. de Sousa Pinheiro, A.J.G. Castro, M. da Silva Nascimento Santos, E.M. Soriano, E.L. Leite, Potential anti-angiogenic, antiproliferative, antioxidant, and anticoagulant activity of anionic polysaccharides, fucans, extracted from brown algae Lobophora variegata, Journal of Applied Phycology. 27 (2015) 1315–1325. https://doi.org/10.1007/s10811-014-0424-1.
[26] J. Zucman-Rossi, A. Villanueva, J.C. Nault, J.M. Llovet, Genetic Landscape and Biomarkers of Hepatocellular Carcinoma, Gastroenterology. 149 (2015) 1226-1239.e4. https://doi.org/10.1053/j.gastro.2015.05.061.
[27] B. He, J. Yin, S. Gong, J. Gu, J. Xiao, W. Shi, W. Ding, Y. He, E. Janczewska, Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis, Medicine (United States). 96 (2017). https://doi.org/10.1097/MD.0000000000006938.
[28] L. Zhou, Y. Du, L. Kong, X. Zhang, Q. Chen, Identification of molecular target genes and key pathways in hepatocellular carcinoma by bioinformatics analysis, OncoTargets and Therapy. 11 (2018) 1861–1869. https://doi.org/10.2147/OTT.S156737.
[29] T. Barrett, S.E. Wilhite, P. Ledoux, C. Evangelista, I.F. Kim, M. Tomashevsky, K.A. Marshall, K.H. Phillippy, P.M. Sherman, M. Holko, A. Yefanov, H. Lee, N. Zhang, C.L. Robertson, N. Serova, S. Davis, A. Soboleva, NCBI GEO: Archive for functional genomics data sets - Update, Nucleic Acids Research. 41 (2013). https://doi.org/10.1093/nar/gks1193.
[30] E. Clough, T. Barrett, The Gene Expression Omnibus database, in: Methods in Molecular Biology, 2016: pp. 93–110. https://doi.org/10.1007/978-1-4939-3578-9_5.
[31] K. Schulze, et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nature Genetics. 47 (2015) 505–511. https://doi.org/10.1038/ng.3252.
[32] M. Ashburner, C.A. Ball, J.A. Blake, D. Botstein, H. Butler, J.M. Cherry, A.P. Davis, K. Dolinski, S.S. Dwight, J.T. Eppig, M.A. Harris, D.P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J.C. Matese, J.E. Richardson, M. Ringwald, G.M. Rubin, G. Sherlock, Gene ontology: Tool for the unification of biology, Nature Genetics. 25 (2000) 25–29. https://doi.org/10.1038/75556.
[33] M. Kanehisa, S. Goto, S. Kawashima, Y. Okuno, M. Hattori, The KEGG resource for deciphering the genome, Nucleic Acids Research. 32 (2004). https://doi.org/10.1093/nar/gkh063.
[34] D. Szklarczyk, A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Cepas, M. Simonovic, A. Roth, A. Santos, K.P. Tsafou, M. Kuhn, P. Bork, L.J. Jensen, C. Von Mering, STRING v10: Protein-protein interaction networks, integrated over the tree of life, Nucleic Acids Research. 43 (2015) D447–D452. https://doi.org/10.1093/nar/gku1003.
[35] C.H. Chin, S.H. Chen, H.H. Wu, C.W. Ho, M.T. Ko, C.Y. Lin, cytoHubba: Identifying hub objects and sub-networks from complex interactome, BMC Systems Biology. 8 (2014). https://doi.org/10.1186/1752-0509-8-S4-S11.
[36] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, Z. Zhang, GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses, Nucleic Acids Research. 45 (2017) W98–W102. https://doi.org/10.1093/nar/gkx247.
[37] G. Bindea, B. Mlecnik, H. Hackl, P. Charoentong, M. Tosolini, A. Kirilovsky, W.H. Fridman, F. Pagès, Z. Trajanoski, J. Galon, ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks, Bioinformatics. 25 (2009) 1091–1093. https://doi.org/10.1093/bioinformatics/btp101.
[38] X. Liu, J. Wu, D. Zhang, Z. Bing, J. Tian, M. Ni, X. Zhang, Z. Meng, S. Liu, Identification of potential key genes associated with the pathogenesis and prognosis of gastric cancer based on integrated bioinformatics analysis, Frontiers in Genetics. 9 (2018). https://doi.org/10.3389/fgene.2018.00265.
[39] C.X. Wu, X.Q. Wang, S.H. Chok, K. Man, S.H.Y. Tsang, A.C.Y. Chan, K.W. Ma, W. Xia, T.T. Cheung, Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma, Theranostics. 8 (2018) 3737–3750. https://doi.org/10.7150/thno.25487.
[40] Y. Zhang, W. Huang, Y. Ran, Y. Xiong, Z. Zhong, X. Fan, Z. Wang, Q. Ye, miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3, Tumor Biology. 36 (2015) 8309–8316. https://doi.org/10.1007/s13277-015-3582-0.
[41] Y. Ito, T. Takeda, M. Sakon, M. Monden, M. Tsujimoto, N. Matsuura, Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma, Oncology. 59 (2000) 68–74. https://doi.org/10.1159/000012140.
[42] L. Gopinathan, S.L.W. Tan, V.C. Padmakumar, V. Coppola, L. Tessarollo, P. Kaldis, Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis, Cancer Research. 74 (2014) 3870–3879. https://doi.org/10.1158/0008-5472.CAN-13-3440.
[43] F. Yang, J. Gong, G. Wang, P. Chen, L. Yang, Z. Wang, Waltonitone inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway, Oncotarget. 7 (2016) 75165–75175. https://doi.org/10.18632/oncotarget.12614.
[44] I.R.K. Bukholm, G. Bukholm, J.M. Nesland, Over-expression of cyclin a is highly associated with early relapse and reduced survival in patients with primary breast carcinomas, International Journal of Cancer. 93 (2001) 283–287. https://doi.org/10.1002/ijc.1311.
[45] N. Chai, H. hong Xie, J. peng Yin, K. di Sa, Y. Guo, M. Wang, J. Liu, X. fang Zhang, X. Zhang, H. Yin, Y. zhan Nie, K. chun Wu, A. gang Yang, R. Zhang, FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1, Biochemical and Biophysical Research Communications. 500 (2018) 924–929. https://doi.org/10.1016/j.bbrc.2018.04.201.
[46] J. Gu, X. Liu, J. Li, Y. He, MicroRNA-144 inhibits cell proliferation, migration and invasion in human hepatocellular carcinoma by targeting CCNB1 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis, Cancer Cell International. 19 (2019). https://doi.org/10.1186/s12935-019-0729-x.
[47] G. Wang, H. Chen, M. Huang, N. Wang, J. Zhang, Y. Zhang, G. Bai, W.F. Fong, M. Yang, X. Yao, Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells, Cancer Letters. 241 (2006) 102–109. https://doi.org/10.1016/j.canlet.2005.10.050.
[48] R. Li, X. Jiang, Y. Zhang, S. Wang, X. Chen, X. Yu, J. Ma, X. Huang, Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis, Archives of Medical Research. 50 (2019) 10–17. https://doi.org/10.1016/j.arcmed.2019.03.003.
[49] E. Shubbar, A. Kovács, S. Hajizadeh, T.Z. Parris, S. Nemes, K. Gunnarsdóttir, Z. Einbeigi, P. Karlsson, K. Helou, Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome, BMC Cancer. 13 (2013). https://doi.org/10.1186/1471-2407-13-1.
[50] B. Xu, T. Xu, H. Liu, Q. Min, S. Wang, Q. Song, MiR-490-5p Suppresses Cell Proliferation and Invasion by Targeting BUB1 in Hepatocellular Carcinoma Cells, Pharmacology. 100 (2017) 269–282. https://doi.org/10.1159/000477667.
[51] R.M. Ricke, K.B. Jeganathan, J.M. van Deursen, Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation, Journal of Cell Biology. 193 (2011) 1049–1064. https://doi.org/10.1083/jcb.201012035.
[52] A.W. Liu, J. Cai, X.L. Zhao, A.M. Xu, H.Q. Fu, H. Nian, S.H. Zhang, The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma, Journal of Clinical Pathology. 62 (2009) 1003–1008. https://doi.org/10.1136/jcp.2009.066944.
[53] L.L. Ju, L. Chen, J.H. Li, Y.F. Wang, R.J. Lu, Z.L. Bian, J.G. Shao, Effect of NDC80 in human hepatocellular carcinoma, World Journal of Gastroenterology. 23 (2017) 3675–3683. https://doi.org/10.3748/wjg.v23.i20.3675.
[54] Q.C. Meng, H.C. Wang, Z.L. Song, Z.Z. Shan, Z. Yuan, Q. Zheng, X.Y. Huang, Overexpression of NDC80 is correlated with prognosis of pancreatic cancer and regulates cell proliferation, American Journal of Cancer Research. 5 (2015) 1730–1740.
[55] K. Liu, Y. Li, B. Yu, F. Wang, T. Mi, Y. Zhao, Silencing non-smc chromosome-associated polypeptide g inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells, Canadian Journal of Physiology and Pharmacology. 96 (2018) 1246–1254. https://doi.org/10.1139/cjpp-2018-0195.
[56] J. Li, J.Z. Gao, J.L. Du, Z.X. Huang, L.X. Wei, Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma, International Journal of Oncology. 45 (2014) 1547–1555. https://doi.org/10.3892/ijo.2014.2559.
[57] M. Liu, Y. Zhang, Y. Liao, Y. Chen, Y. Pan, H. Tian, Y. Zhan, D. Liu, Evaluation of the Antitumor Efficacy of RNAi-Mediated Inhibition of CDC20 and Heparanase in an Orthotopic Liver Tumor Model, Cancer Biotherapy and Radiopharmaceuticals. 30 (2015) 233–239. https://doi.org/10.1089/cbr.2014.1799.
[58] Y. Li, W. Bai, J. Zhang, MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1, Biomedicine and Pharmacotherapy. 92 (2017) 1038–1044. https://doi.org/10.1016/j.biopha.2017.05.092.